Oruka Therapeutics is trying to turn two of the most validated immunology targets into injectables that patients receive once or twice a year rather than every other month. April's mid-stage psoriasis readout on the interleukin-twenty-three antibody produced complete skin clearance in a majority of treated patients and immediately unlocked a follow-on that recapitalized the company through a planned biologics application. The equity debate is no longer whether the mechanism works. It is whether durability, dose selection, and a later registrational program justify an enterprise value that already treats Oruka as a franchise rather than a single mid-stage experiment.
The cash hoard is real and almost unlevered, and that is both the cushion and the tell. Liquidity above one billion sits against a market capitalization near six billion, so the tape is already paying for a de-risked registrational path plus optional expansion into hidradenitis, combinations, and eventually bowel disease. The strongest counterargument is that complete-clearance rates from a single mid-stage cohort do not yet prove once-yearly maintenance, and incumbents such as Skyrizi and Bimzelx already own the dermatology call point. A miss on six-month durability would not bankrupt the company. It would collapse the multiple the April raise helped create.
Second-quarter spending confirms the company is acting like a pre-commercial organization rather than a discovery shop. Research costs jumped as both co-lead antibodies moved through mid-stage trials, while interest income on the new cash pile offset only a slice of the loss. The next several months resolve the yearly-dosing claim, the dose that enters the registrational program, and whether the interleukin-seventeen twin can open a second commercial door. Does clearance hold when the calendar, not the syringe, does the work?